GILD logo

GILEAD SCIENCES INC

GILDNASDAQ
πŸ† #59 by market cap🧬Biotech
$166.43β€”
Last available close Β· quote unavailable
πŸ””
Track GILD
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–Ό 1.0%
14dβ–Ό 0.3%
30dβ–² 6.6%
ytdβ–² 35.6%
1yβ–² 31.3%
🏦Market Cap
$206.43B
Large Cap
πŸ“ˆRevenue Growth (YoY)
6.5%
Slowing
πŸ“ŠGross Margin
80.0%
High
πŸ’΅FCF Margin
44.5%
Strong
βš–οΈP/S Ratio
6.7x
Fair
Otter Score
80
Strong

Trading Snapshot

Day Range
β€”
52-Week Range
$116.88 – $176.58
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
1.24B
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
6.7x
EPS (TTM)
$-3.15
Dividend Yield
1.95%
Dilution (1yr)
βˆ’0.5%
GILD logo

GILEAD SCIENCES INC

GILD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$29.4Bβ–² +2.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
78.8%β–² +0.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$11.7Bβ–² +604.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$9.5Bβ–Ό βˆ’8.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.25Bβ–Ό βˆ’0.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$17.4Bβ–Ό βˆ’$41M YoY
StockOtter Β· stockotter.space

About GILEAD SCIENCES INC

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
80/100
Analyst data unavailable.

Latest News & Updates

News unavailable.